WW — WW International, Inc.

Is WW overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Care Facilities

Oversold As of October 3, 2026

WW International, Inc. (WW) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Care Facilities) last closed at $14.74. The rating moved from Overbought to Oversold on October 1, 2026.

See all oversold Healthcare stocks →

AI analysis

WW International, Inc. (WW) is supported by a recognizable brand and recurring subscription model plus an expanding digital and product mix that can drive higher customer LTV if retention and monetization improve. However, the company faces significant near-term headwinds: rapid uptake of GLP-1 therapies is reshaping the weight-management market, macro-driven discretionary weakness and a risk-off market tone can depress growth, and execution is critical given limited near-term filing/financial visibility. Watch for signs of sustainable ARPU growth, improving retention metrics, margin recovery and meaningful partnership or product rollouts as positive catalysts; conversely, accelerating churn, slowing sales of higher-margin offerings, or worsening macro conditions would materially pressure results.

Key factors

  • Strong consumer brand and long-standing subscription model with recurring revenue potential
  • Diversified digital offerings (coaching, app, community) and product/food portfolio that can increase ARPU if monetized effectively
  • Vulnerability to rapid adoption of GLP-1 and other obesity drugs which can materially reduce demand for traditional weight-loss programs
  • Macroeconomic and risk-off market tone likely to weigh discretionary consumer spending on wellness services
  • Limited visibility into near-term financials (no fresh EDGAR filings provided) increases reliance on execution and cadence of reported metrics
  • Potential catalysts: new partnerships, product innovations, improved retention/monetization, and any margin recovery or cost optimization

Risks

  • Broad adoption of GLP-1/T2D obesity medications reducing addressable market for subscription weight-loss services
  • Execution risk on converting users to higher-margin product and services (retention, ARPU uplift)
  • Weak consumer spending and discretionary budget compression in a risk-off macro environment
  • Competitive pressures from other digital health, fitness, and wellness platforms and new entrants
  • Operational/liquidity risk if revenue decelerates and cost structure is not adjusted promptly
  • Regulatory or payer shifts that alter affordability dynamics for weight-management solutions

See today's live rating, score and targets

Members see the live hourly rating for WW — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.